Tafolecimab (IBI-306) is a human IgG2 monoclonal antibody designed to specifically target and bind to proprotein convertase subtilisin/kexin type 9 (PCSK9). By binding to PCSK9, Tafolecimab effectively inhibits PCSK9-mediated endocytosis of low-density lipoprotein (LDL) receptors, thereby enhancing the clearance of LDL cholesterol (LDL-C) from the bloodstream. This mechanism leads to a significant reduction in LDL-C levels, making Tafolecimab a valuable tool for research into hypercholesterolemia and potential therapeutic interventions.
Tafolecimab (IBI-306) is a human IgG2 monoclonal antibody designed to specifically target and bind to proprotein convertase subtilisin/kexin type 9 (PCSK9). By binding to PCSK9, Tafolecimab effectively inhibits PCSK9-mediated endocytosis of low-density lipoprotein (LDL) receptors, thereby enhancing the clearance of LDL cholesterol (LDL-C) from the bloodstream. This mechanism leads to a significant reduction in LDL-C levels, making Tafolecimab a valuable tool for research into hypercholesterolemia and potential therapeutic interventions.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
